Ísrael - hebreska - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 50 mg; carbidopa 12.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor

Ísrael - hebreska - Ministry of Health

inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - טבליות מצופות פילם - levodopa 125 mg; entacapone 200 mg; carbidopa as monohydrate 31.25 mg - levodopa

Ísrael - hebreska - Ministry of Health

inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - טבליות מצופות פילם - levodopa 200 mg; entacapone 200 mg; carbidopa as monohydrate 50 mg - levodopa and decarboxylase inhibitor

Ísrael - hebreska - Ministry of Health

inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - טבליות מצופות פילם - levodopa 200 mg; entacapone 200 mg; carbidopa as monohydrate 50 mg - levodopa and decarboxylase inhibitor

Ísrael - hebreska - Ministry of Health

inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - טבליות מצופות פילם - carbidopa as monohydrate 18.75 mg; entacapone 200 mg; levodopa 75 mg - levodopa

Ísrael - hebreska - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride 2 mg - film coated tablets - prolonged release - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

Ísrael - hebreska - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - טבליות מצופות פילם - שחרור ממושך - ropinirole as hydrochloride 2 mg - ropinirole - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

Ísrael - hebreska - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride 8 mg - film coated tablets - prolonged release - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

Ísrael - hebreska - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - טבליות מצופות פילם - שחרור ממושך - ropinirole as hydrochloride 8 mg - ropinirole - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

Ísrael - hebreska - Ministry of Health

glaxo smith kline (israel) ltd - ropinirole as hydrochloride 4 mg - film coated tablets - prolonged release - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.